Shanghai Biopharma Fund II, managed by SIIC Capital and sponsored with industrial anchors including Shanghai Pharmaceuticals and Junshi Biosciences, has held its first close at RMB 1.5 billion (USD 222 million) against a RMB 2.0 billion target. Other limited partners (LPs) include Shanghai State-owned Capital Investment, PDVC, GTJA, and ZK-JI Park, reflecting a deliberate blend of state-backed capital, corporate strategics and financial investors. The fund will concentrate on assets moving from Investigational New Drug (IND) stage through Phase II, spanning innovative small molecules, biologics and medical devices across metabolism, cardiovascular, oncology and autoimmunity.

The strategy deliberately occupies the optimal risk-adjusted return window of drug development – beyond early discovery, yet ahead of expensive pivotal trials – where technical and regulatory validation begins to lower binary risk. Embedded in SIIC Capital's broader matrix (Phase I growth fund, translation fund, buyout fund, and Hong Kong biotech fund), the vehicle enables a full-cycle ecosystem from lab to commercialisation and from domestic to cross-border exit. For industrial LPs such as Shanghai Pharma, the structure supplies a curated early-stage pipeline to feed business development and in-licensing needs, converting capital deployment into strategic optionality rather than pure financial yield.